Enhancing the utility of existing antibiotics by targeting bacterial behaviour?

British Journal of Pharmacology

Volumn 165, Issue 4, 2012, Pages 845-857

  Rogers, Geraint B ^a   Carroll, Mary P ^b   Bruce, Kenneth D ^a  

^a Molecular Microbiology Research Laboratory   (United Kingdom)

^b UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

antibiotic resistance; bacteriophage therapy; biofilm; macrolide antibiotics; persister; quorum sensing; viable non culturable

Indexed keywords

AMITRIPTYLINE; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; APRAMYCIN; AVIBACTAM; AZITHROMYCIN; CEFTAZIDIME; CHLORPROMAZINE; CHLORPROTHIXENE; CIPROFLOXACIN; ERYTHROMYCIN; FURANONE DERIVATIVE; GENTAMICIN; ISONIAZID; MACROLIDE; METRONIDAZOLE; OXAZOLIDINONE DERIVATIVE; TETRAZOLE DERIVATIVE; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; BACTERIAL CELL; BACTERIAL GENE; BACTERIAL INFECTION; BACTERIOPHAGE; BIOFILM; DRUG EFFICACY; DRUG POTENTIATION; DRUG TARGETING; DRUG USE; EVIDENCE BASED MEDICINE; HUMAN; IC 50; LUNG INFECTION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PERSISTENT INFECTION; PRESCRIPTION; PRIORITY JOURNAL; QUORUM SENSING; REVIEW;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; BACTERIAL PHYSIOLOGICAL PHENOMENA; BIOFILMS; HUMANS; QUORUM SENSING; TREATMENT OUTCOME;

EID: 84856264444     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01643.x     Document Type: Review

References (189)

1. Antunes LC, Ferreira RB, (2009). Intercellular communication in bacteria. Crit Rev Microbiol 35: 69-80.
2. Antunes LC, Ferreira RB, Buckner MM, Finlay BB, (2010). Quorum sensing in bacterial virulence. Microbiology 156: 2271-2282.
3. Attila C, Ueda A, Wood TK, (2009). 5-Fluorouracil reduces biofilm formation in Escherichia coli K-12 through global regulator AriR as an antivirulence compound. Appl Microbiol Biotechnol 82: 525-533.
4. Barraud N, Hassett DJ, Hwang SH, Rice SA, Kjelleberg S, Webb JS, (2006). Involvement of nitric oxide in biofilm dispersal of Pseudomonas aeruginosa. J Bacteriol 188: 7344-7353. (Pubitemid 44646233)
5. Barraud N, Schleheck D, Klebensberger J, Webb JS, Hassett DJ, Rice SA, et al,. (2009a). Nitric oxide signaling in Pseudomonas aeruginosa biofilms mediates phosphodiesterase activity, decreased cyclic di-GMP levels, and enhanced dispersal. J Bacteriol 191: 7333-7342.
6. Barraud N, Storey MV, Moore ZP, Webb JS, Rice SA, Kjelleberg S, (2009b). Nitric oxide-mediated dispersal in single- and multi-species biofilms of clinically and industrially relevant microorganisms. Microb Biotechnol 2: 370-378.
7. Bartlett JG, (1999) Letter to Public Health and Safety Subcommittee, Infectious Diseases Society of America.
8. Bassler BL, (1999). How bacteria talk to each other: regulation of gene expression by quorum sensing. Curr Opin Microbiol 2: 582-587.
9. Beenken KE, Dunman PM, McAleese F, Macapagal D, Murphy E, Projan SJ, et al,. (2004). Global gene expression in Staphylococcus aureus biofilms. J Bacteriol 186: 4665-4684. (Pubitemid 38891030)
10. Ben-David D, Rubinstein E, (2002). Appropriate use of antibiotics for respiratory infections: review of recent statements and position papers. Curr Opin Infect Dis 15: 151-156. (Pubitemid 34271158)
11. Bjarnsholt T, Givskov M, (2008). Quorum sensing inhibitory drugs as next generation antimicrobials: worth the effort? Curr Infect Dis Rep 10: 22-28. (Pubitemid 351419359)
12. Bjarnsholt T, Jensen PO, Burmolle M, Hentzer M, Haagensen JA, Hougen HP, et al,. (2005). Pseudomonas aeruginosa tolerance to tobramycin, hydrogen peroxide and polymorphonuclear leukocytes is quorum-sensing dependent. Microbiology 151: 373-383. (Pubitemid 40277742)
13. Black DS, Kelly AJ, Mardis MJ, Moyed HS, (1991). Structure and organization of hip, an operon that affects lethality due to inhibition of peptidoglycan or DNA synthesis. J Bacteriol 173: 5732-5739.
14. Black DS, Irwin B, Moyed HS, (1994). Autoregulation of hip, an operon that affects lethality due to inhibition of peptidoglycan or DNA synthesis. J Bacteriol 176: 4081-4091. (Pubitemid 24191293)
15. Borysowski J, Weber-Dabrowska B, Gorski A, (2006). Bacteriophage endolysins as a novel class of antibacterial agents. Exp Biol Med (Maywood) 231: 366-377.
16. Boyd A, Chakrabarty AM, (1995). Pseudomonas aeruginosa biofilms: role of the alginate exopolysaccharide. J Ind Microbiol 15: 162-168.
17. Brackman G, Cos P, Maes L, Nelis HJ, Coenye T, (2011). Quorum sensing inhibitors increase the susceptibility of bacterial biofilms to antibiotics in vitro and in vivo. Antimicrob Agents Chemother 55: 2655-2661.
18. Brooun A, Liu S, Lewis K, (2000). A dose-response study of antibiotic resistance in Pseudomonas aeruginosa biofilms. Antimicrob Agents Chemother 44: 640-646. (Pubitemid 30117954)
19. Brussow H, (2005). Phage therapy: the Escherichia coli experience. Microbiology 151: 2133-2140. (Pubitemid 40984287)
20. Bryk R, Gold B, Venugopal A, Singh J, Samy R, Pupek K, et al,. (2008). Selective killing of nonreplicating mycobacteria. Cell Host Microbe 3: 137-145. (Pubitemid 351325759)
21. Butler MS, Cooper MA, (2011). Antibiotics in the clinical pipeline in 2011. J Antibiot (Tokyo) 64: 413-425.
22. Centers for Disease Control and Prevention (2006). The race against resistance creates urgency for the development of new antimicrobials.
23. Chaslus-Dancla E, Pohl P, Meurisse M, Marin M, Lafont JP, (1991). High genetic homology between plasmids of human and animal origins conferring resistance to the aminoglycosides gentamicin and apramycin. Antimicrob Agents Chemother 35: 590-593.
24. Chattoraj SS, Ganesan S, Jones AM, Helm JM, Comstock AT, Bright-Thomas R, et al,. (2011). Rhinovirus infection liberates planktonic bacteria from biofilm and increases chemokine responses in cystic fibrosis airway epithelial cells. Thorax 66: 333-339.
25. Coates AR, Hu Y, (2007). Novel approaches to developing new antibiotics for bacterial infections. Br J Pharmacol 152: 1147-1154. (Pubitemid 350242433)
26. Coates AR, Hu Y, (2008). Targeting non-multiplying organisms as a way to develop novel antimicrobials. Trends Pharmacol Sci 29: 143-150.
27. Coates A, Hu Y, Bax R, Page C, (2002). The future challenges facing the development of new antimicrobial drugs. Nat Rev Drug Discov 1: 895-910. (Pubitemid 37361584)
28. Coates AR, Halls G, Hu Y, (2011). Novel classes of antibiotics or more of the same? Br J Pharmacol 163: 184-194.
29. Cooke FJ, Matar R, Lawson W, Aliyu SH, Holmes A, (2010). Comment on: antibiotic stewardship-more education and regulation not more availability? J Antimicrob Chemother 65: 598.
30. Correia FF, D'Onofrio A, Rejtar T, Li L, Karger BL, Makarova K, et al,. (2006). Kinase activity of overexpressed HipA is required for growth arrest and multidrug tolerance in Escherichia coli. J Bacteriol 188: 8360-8367. (Pubitemid 44894035)
31. Costerton JW, Lewandowski Z, Caldwell DE, Korber DR, Lappin-Scott HM, (1995). Microbial biofilms. Annu Rev Microbiol 49: 711-745.
32. Curtin JJ, Donlan RM, (2006). Using bacteriophages to reduce formation of catheter-associated biofilms by Staphylococcus epidermidis. Antimicrob Agents Chemother 50: 1268-1275.
33. Cusini A, Rampini SK, Bansal V, Ledergerber B, Kuster SP, Ruef C, et al,. (2010). Different patterns of inappropriate antimicrobial use in surgical and medical units at a tertiary care hospital in Switzerland: a prevalence survey. PLoS ONE 5: e14011.
34. Cystic Fibrosis Trust (2009) Antibiotic treatment for cystic fibrosis-report of the UK cystic fibrosis antibiotic working group.
35. Dabrowska K, Opolski A, Wietrzyk J, Switala-Jelen K, Boratynski J, Nasulewicz A, et al,. (2004). Antitumor activity of bacteriophages in murine experimental cancer models caused possibly by inhibition of beta3 integrin signalling pathway. Acta Virol 48: 241-248. (Pubitemid 47434295)
36. Darouiche RO, Mansouri MD, Gawande PV, Madhyastha S, (2009). Antimicrobial and antibiofilm efficacy of triclosan and DispersinB combination. J Antimicrob Chemother 64: 88-93.
37. Davey ME, Caiazza NC, O'Toole GA, (2003). Rhamnolipid surfactant production affects biofilm architecture in Pseudomonas aeruginosa PAO1. J Bacteriol 185: 1027-1036. (Pubitemid 36139462)
38. Davies J, (2006). Where have all the antibiotics gone? Can J Infect Dis Med Microbiol 17: 287-290. (Pubitemid 44898667)
39. Davies J, (2011). How to discover new antibiotics: harvesting the parvome. Curr Opin Chem Biol 15: 5-10.
40. De Groote MA, Fang FC, (1995). NO inhibitions: antimicrobial properties of nitric oxide. Clin Infect Dis 21 (Suppl. 2): S162-S165.
41. De Groote VN, Fauvart M, Kint CI, Verstraeten N, Jans A, Cornelis P, et al,. (2011). Pseudomonas aeruginosa fosfomycin resistance mechanisms affect non-inherited fluoroquinolone tolerance. J Med Microbiol 60: 329-336.
42. De Leenheer P, Cogan NG, (2009). Failure of antibiotic treatment in microbial populations. J Math Biol 59: 563-579.
43. Debbia EA, Roveta S, Schito AM, Gualco L, Marchese A, (2001). Antibiotic persistence: the role of spontaneous DNA repair response. Microb Drug Resist 7: 335-342. (Pubitemid 34106307)
44. Dellit TH, Owens RC, McGowan JE Jr, Gerding DN, Weinstein RA, Burke JP, et al,. (2007). Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 44: 159-177. (Pubitemid 46084814)
45. DiMasi JA, Hansen RW, Grabowski HG, (2003). The price of innovation: new estimates of drug development costs. J Health Econ 22: 151-185. (Pubitemid 36279392)
46. Donelli G, Francolini I, Romoli D, Guaglianone E, Piozzi A, Ragunath C, et al,. (2007). Synergistic activity of dispersin B and cefamandole nafate in inhibition of staphylococcal biofilm growth on polyurethanes. Antimicrob Agents Chemother 51: 2733-2740. (Pubitemid 47206207)
47. Dong YH, Xu JL, Li XZ, Zhang LH, (2000). AiiA, an enzyme that inactivates the acylhomoserine lactone quorum-sensing signal and attenuates the virulence of Erwinia carotovora. Proc Natl Acad Sci U S A 97: 3526-3531.
48. Dong YH, Wang LH, Xu JL, Zhang HB, Zhang XF, Zhang LH, (2001). Quenching quorum-sensing-dependent bacterial infection by an N-acyl homoserine lactonase. Nature 411: 813-817.
49. Dong YH, Wang LY, Zhang LH, (2007). Quorum-quenching microbial infections: mechanisms and implications. Philos Trans R Soc Lond B Biol Sci 362: 1201-1211.
50. Dorr T, Lewis K, Vulic M, (2009). SOS response induces persistence to fluoroquinolones in Escherichia coli. PLoS Genet 5: e1000760.
51. Dorr T, Vulic M, Lewis K, (2010). Ciprofloxacin causes persister formation by inducing the TisB toxin in Escherichia coli. PLoS Biol 8: e1000317.
52. Doyle MP, Erickson MC, (2006). Reducing the carriage of foodborne pathogens in livestock and poultry. Poult Sci 85: 960-973. (Pubitemid 46063333)
53. Dryden MS, Cooke J, Davey P, (2009). Antibiotic stewardship-more education and regulation not more availability? J Antimicrob Chemother 64: 885-888.
54. Dworkin J, Shah IM, (2010). Exit from dormancy in microbial organisms. Nat Rev Microbiol 8: 890-896.
55. Eberl L, (1999). N-acyl homoserinelactone-mediated gene regulation in gram-negative bacteria. Syst Appl Microbiol 22: 493-506. (Pubitemid 30093252)
56. Endimiani A, Hujer KM, Hujer AM, Pulse ME, Weiss WJ, Bonomo RA, (2011). Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother 55: 82-85.
57. Equi A, Balfour-Lynn IM, Bush A, Rosenthal M, (2002). Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet 360: 978-984. (Pubitemid 35284109)
58. Falla TJ, Chopra I, (1998). Joint tolerance to beta-lactam and fluoroquinolone antibiotics in Escherichia coli results from overexpression of hipA. Antimicrob Agents Chemother 42: 3282-3284. (Pubitemid 28553755)
59. Fauvart M, De Groote VN, Michiels J, (2011). Role of persister cells in chronic infections: clinical relevance and perspectives on anti-persister therapies. J Med Microbiol 60: 699-709.
60. Fernandes P, (2006). Antibacterial discovery and development-the failure of success? Nat Biotechnol 24: 1497-1503. (Pubitemid 44967469)
61. Fischbach MA, Walsh CT, (2009). Antibiotics for emerging pathogens. Science 325: 1089-1093.
62. Fischetti VA, Nelson D, Schuch R, (2006). Reinventing phage therapy: are the parts greater than the sum? Nat Biotechnol 24: 1508-1511. (Pubitemid 44967471)
63. Food and Drug Administration, Department of Health and Human Services (2009). Summary report on Antimicrobials Sold or Distributed for Use in Food-Producing Animals.
64. Fu W, Forster T, Mayer O, Curtin JJ, Lehman SM, Donlan RM, (2010). Bacteriophage cocktail for the prevention of biofilm formation by Pseudomonas aeruginosa on catheters in an in vitro model system. Antimicrob Agents Chemother 54: 397-404.
65. Fuqua WC, Winans SC, Greenberg EP, (1994). Quorum sensing in bacteria: the LuxR-LuxI family of cell density-responsive transcriptional regulators. J Bacteriol 176: 269-275. (Pubitemid 24034041)
66. Fuqua C, Parsek MR, Greenberg EP, (2001). Regulation of gene expression by cell-to-cell communication: acyl-homoserine lactone quorum sensing. Annu Rev Genet 35: 439-468. (Pubitemid 34032983)
67. Gilbert DN, Edwards JE Jr, (2002). Is there hope for the prevention of future antimicrobial shortages? Clin Infect Dis 35: 215-216. Author reply 216-217.
68. Gjermansen M, Ragas P, Sternberg C, Molin S, Tolker-Nielsen T, (2005). Characterization of starvation-induced dispersion in Pseudomonas putida biofilms. Environ Microbiol 7: 894-906. (Pubitemid 40697647)
69. Grigoryan L, Monnet DL, Haaijer-Ruskamp FM, Bonten MJ, Lundborg S, Verheij TJ, (2010). Self-medication with antibiotics in Europe: a case for action. Curr Drug Saf 5: 329-332.
70. Hagens S, Blasi U, (2003). Genetically modified filamentous phage as bactericidal agents: a pilot study. Lett Appl Microbiol 37: 318-323. (Pubitemid 37186625)
71. Hagens S, Habel A, von Ahsen U, von Gabain A, Blasi U, (2004). Therapy of experimental pseudomonas infections with a nonreplicating genetically modified phage. Antimicrob Agents Chemother 48: 3817-3822. (Pubitemid 39304609)
72. Han Y, Chen F, Li N, Zhu B, Li X, (2010). Bacillus marcorestinctum sp. nov., a novel soil acylhomoserine lactone quorum-sensing signal quenching bacterium. Int J Mol Sci 11: 507-520.
73. Hansen S, Lewis K, Vulic M, (2008). Role of global regulators and nucleotide metabolism in antibiotic tolerance in Escherichia coli. Antimicrob Agents Chemother 52: 2718-2726.
74. Hart CA, Kariuki S, (1998). Antimicrobial resistance in developing countries. BMJ 317: 647-650. (Pubitemid 28403493)
75. Heitman J, Fulford W, Model P, (1989). Phage Trojan horses: a conditional expression system for lethal genes. Gene 85: 193-197. (Pubitemid 20054343)
76. Hentzer M, Givskov M, (2003). Pharmacological inhibition of quorum sensing for the treatment of chronic bacterial infections. J Clin Invest 112: 1300-1307. (Pubitemid 38057681)
77. Hentzer M, Riedel K, Rasmussen TB, Heydorn A, Andersen JB, Parsek MR, et al,. (2002). Inhibition of quorum sensing in Pseudomonas aeruginosa biofilm bacteria by a halogenated furanone compound. Microbiology 148: 87-102. (Pubitemid 34083188)
78. Hetrick EM, Shin JH, Stasko NA, Johnson CB, Wespe DA, Holmuhamedov E, et al,. (2008). Bactericidal efficacy of nitric oxide-releasing silica nanoparticles. ACS Nano 2: 235-246. (Pubitemid 351585938)
79. Hetrick EM, Shin JH, Paul HS, Schoenfisch MH, (2009). Anti-biofilm efficacy of nitric oxide-releasing silica nanoparticles. Biomaterials 30: 2782-2789.
80. Hoffmann N, Lee B, Hentzer M, Rasmussen TB, Song Z, Johansen HK, et al,. (2007). Azithromycin blocks quorum sensing and alginate polymer formation and increases the sensitivity to serum and stationary-growth-phase killing of Pseudomonas aeruginosa and attenuates chronic P. aeruginosa lung infection in Cftr(-/-) mice. Antimicrob Agents Chemother 51: 3677-3687. (Pubitemid 47519359)
81. Hogberg LD, Heddini A, Cars O, (2010). The global need for effective antibiotics: challenges and recent advances. Trends Pharmacol Sci 31: 509-515.
82. Howe RA, Spencer RC, (1997). Macrolides for the treatment of Pseudomonas aeruginosa infections? J Antimicrob Chemother 40: 153-155. (Pubitemid 27394006)
83. Hu Y, Coates AR, (1999a). Transcription of the stationary-phase- associated hspX gene of Mycobacterium tuberculosis is inversely related to synthesis of the 16-kilodalton protein. J Bacteriol 181: 1380-1387. (Pubitemid 29110794)
84. Hu Y, Coates AR, (1999b). Transcription of two sigma 70 homologue genes, sigA and sigB, in stationary-phase Mycobacterium tuberculosis. J Bacteriol 181: 469-476. (Pubitemid 29045137)
85. Hu Z, Hidalgo G, Houston PL, Hay AG, Shuler ML, Abruna HD, et al,. (2005). Determination of spatial distributions of zinc and active biomass in microbial biofilms by two-photon laser scanning microscopy. Appl Environ Microbiol 71: 4014-4021. (Pubitemid 40980574)
86. Huff WE, Huff GR, Rath NC, Balog JM, Donoghue AM, (2003). Evaluation of aerosol spray and intramuscular injection of bacteriophage to treat an Escherichia coli respiratory infection. Poult Sci 82: 1108-1112. (Pubitemid 38641651)
87. Hunt SM, Werner EM, Huang B, Hamilton MA, Stewart PS, (2004). Hypothesis for the role of nutrient starvation in biofilm detachment. Appl Environ Microbiol 70: 7418-7425. (Pubitemid 39643808)
88. Infectious Diseases Society of America (IDSA) (2004). Bad bugs, no drugs: as antibiotic R&D stagnates, a public health crisis brews.
89. Itoh Y, Wang X, Hinnebusch BJ, Preston JF 3rd, Romeo T, (2005). Depolymerization of beta-1,6-N-acetyl-D-glucosamine disrupts the integrity of diverse bacterial biofilms. J Bacteriol 187: 382-387. (Pubitemid 40024214)
90. Izano EA, Sadovskaya I, Vinogradov E, Mulks MH, Velliyagounder K, Ragunath C, et al,. (2007). Poly-N-acetylglucosamine mediates biofilm formation and antibiotic resistance in Actinobacillus pleuropneumoniae. Microb Pathog 43: 1-9. (Pubitemid 46678642)
91. Izano EA, Sadovskaya I, Wang H, Vinogradov E, Ragunath C, Ramasubbu N, et al,. (2008). Poly-N-acetylglucosamine mediates biofilm formation and detergent resistance in Aggregatibacter actinomycetemcomitans. Microb Pathog 44: 52-60. (Pubitemid 350236693)
92. Jahoor A, Patel R, Bryan A, Do C, Krier J, Watters C, et al,. (2008). Peroxisome proliferator-activated receptors mediate host cell proinflammatory responses to Pseudomonas aeruginosa autoinducer. J Bacteriol 190: 4408-4415. (Pubitemid 351898956)
93. Janssens JC, Steenackers H, Robijns S, Gellens E, Levin J, Zhao H, et al,. (2008). Brominated furanones inhibit biofilm formation by Salmonella enterica serovar Typhimurium. Appl Environ Microbiol 74: 6639-6648.
94. Johansen SK, Maus CE, Plikaytis BB, Douthwaite S, (2006). Capreomycin binds across the ribosomal subunit interface using tlyA-encoded 2′-O-methylations in 16S and 23S rRNAs. Mol Cell 23: 173-182. (Pubitemid 44081881)
95. Karatan E, Watnick P, (2009). Signals, regulatory networks, and materials that build and break bacterial biofilms. Microbiol Mol Biol Rev 73: 310-347.
96. Kayama S, Murakami K, Ono T, Ushimaru M, Yamamoto A, Hirota K, et al,. (2009). The role of rpoS gene and quorum-sensing system in ofloxacin tolerance in Pseudomonas aeruginosa. FEMS Microbiol Lett 298: 184-192.
97. Keren I, Kaldalu N, Spoering A, Wang Y, Lewis K, (2004). Persister cells and tolerance to antimicrobials. FEMS Microbiol Lett 230: 13-18. (Pubitemid 38091733)
98. Kitchel B, Rasheed JK, Patel JB, Srinivasan A, Navon-Venezia S, Carmeli Y, et al,. (2009). Molecular epidemiology of KPC-producing Klebsiella pneumoniae isolates in the United States: clonal expansion of multilocus sequence type 258. Antimicrob Agents Chemother 53: 3365-3370.
99. Kjelleberg S, Steinberg PD, Givskov M, Gram L, Manefield MJ, De Nys R, (1997). Do marine natural products interfere with prokaryotic AHL regulatory systems? Aquat Microb Ecol 13: 85-93. (Pubitemid 127476500)
100. Kohanski MA, Dwyer DJ, Hayete B, Lawrence CA, Collins JJ, (2007). A common mechanism of cellular death induced by bactericidal antibiotics. Cell 130: 797-810. (Pubitemid 47332566)
101. Kohanski MA, Dwyer DJ, Collins JJ, (2010). How antibiotics kill bacteria: from targets to networks. Nat Rev Microbiol 8: 423-435.
102. Kolodkin-Gal I, Romero D, Cao S, Clardy J, Kolter R, Losick R, (2010). d-amino acids trigger biofilm disassembly. Science 328: 627-629.
103. Korch SB, Hill TM, (2006). Ectopic overexpression of wild-type and mutant hipA genes in Escherichia coli: effects on macromolecular synthesis and persister formation. J Bacteriol 188: 3826-3836. (Pubitemid 43825388)
104. Korch SB, Henderson TA, Hill TM, (2003). Characterization of the hipA7 allele of Escherichia coli and evidence that high persistence is governed by (p)ppGpp synthesis. Mol Microbiol 50: 1199-1213. (Pubitemid 37475853)
105. Kristiansen JE, Thomsen VF, Martins A, Viveiros M, Amaral L, (2010). Non-antibiotics reverse resistance of bacteria to antibiotics. In Vivo 24: 751-754.
106. Kuehl R, Al-Bataineh S, Gordon O, Luginbuehl R, Otto M, Textor M, et al,. (2009). Furanone at subinhibitory concentrations enhances staphylococcal biofilm formation by luxS repression. Antimicrob Agents Chemother 53: 4159-4166.
107. Kumarasamy KK, Toleman MA, Walsh TR, Bagaria J, Butt F, Balakrishnan R, et al,. (2010). Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis 10: 597-602.
108. Lamarche MG, Wanner BL, Crepin S, Harel J, (2008). The phosphate regulon and bacterial virulence: a regulatory network connecting phosphate homeostasis and pathogenesis. FEMS Microbiol Rev 32: 461-473. (Pubitemid 351538744)
109. Landini P, Antoniani D, Burgess JG, Nijland R, (2010). Molecular mechanisms of compounds affecting bacterial biofilm formation and dispersal. Appl Microbiol Biotechnol 86: 813-823.
110. Leadbetter JR, Greenberg EP, (2000). Metabolism of acyl-homoserine lactone quorum-sensing signals by Variovorax paradoxus. J Bacteriol 182: 6921-6926. (Pubitemid 32259594)
111. Lewis K, (2007). Persister cells, dormancy and infectious disease. Nat Rev Microbiol 5: 48-56. (Pubitemid 44942303)
112. Li Y, Zhang Y, (2007). PhoU is a persistence switch involved in persister formation and tolerance to multiple antibiotics and stresses in Escherichia coli. Antimicrob Agents Chemother 51: 2092-2099. (Pubitemid 46903099)
113. Livermore DM, Mushtaq S, Warner M, Zhang J, Maharjan S, Doumith M, et al,. (2011). Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase-producing Enterobacteriaceae. Antimicrob Agents Chemother 55: 390-394.
114. Lu TK, Collins JJ, (2007). Dispersing biofilms with engineered enzymatic bacteriophage. Proc Natl Acad Sci U S A 104: 11197-11202. (Pubitemid 47175118)
115. Lu J, Katano T, Okuda-Ashitaka E, Oishi Y, Urade Y, Ito S, (2009). Involvement of S-nitrosylation of actin in inhibition of neurotransmitter release by nitric oxide. Mol Pain 5: 58.
116. MacDougall C, Polk RE, (2005). Antimicrobial stewardship programs in health care systems. Clin Microbiol Rev 18: 638-656. (Pubitemid 41504509)
117. Manefield M, Turner SL, (2002). Quorum sensing in context: out of molecular biology and into microbial ecology. Microbiology 148: 3762-3764. (Pubitemid 36097437)
118. Manny AJ, Kjelleberg S, Kumar N, de Nys R, Read RW, Steinberg P, (1997). Reinvestigation of the sulfuric acid-catalysed cyclisation of brominated 2-alkyllevulinic acids to 3-alkyl-5-methylene-2(5H)-furanones. Tetrahedron 53: 15813-15826. (Pubitemid 27472968)
119. Matsuda T, Freeman TA, Hilbert DW, Duff M, Fuortes M, Stapleton PP, et al,. (2005). Lysis-deficient bacteriophage therapy decreases endotoxin and inflammatory mediator release and improves survival in a murine peritonitis model. Surgery 137: 639-646. (Pubitemid 40755421)
120. McGregor JC, Perencevich EN, Furuno JP, Langenberg P, Flannery K, Zhu J, et al,. (2006). Comorbidity risk-adjustment measures were developed and validated for studies of antibiotic-resistant infections. J Clin Epidemiol 59: 1266-1273. (Pubitemid 44708614)
121. Medina-Martinez MS, Uyttendaele M, Rajkovic A, Nadal P, Debevere J, (2007). Degradation of N-acyl-L-homoserine lactones by Bacillus cereus in culture media and pork extract. Appl Environ Microbiol 73: 2329-2332. (Pubitemid 46649526)
122. Moker N, Dean CR, Tao J, (2010). Pseudomonas aeruginosa increases formation of multidrug-tolerant persister cells in response to quorum-sensing signaling molecules. J Bacteriol 192: 1946-1955.
123. Morgan R, Kohn S, Hwang SH, Hassett DJ, Sauer K, (2006). BdlA, a chemotaxis regulator essential for biofilm dispersion in Pseudomonas aeruginosa. J Bacteriol 188: 7335-7343. (Pubitemid 44646232)
124. Moyed HS, Broderick SH, (1986). Molecular cloning and expression of hipA, a gene of Escherichia coli K-12 that affects frequency of persistence after inhibition of murein synthesis. J Bacteriol 166: 399-403. (Pubitemid 16112134)
125. Muh U, Schuster M, Heim R, Singh A, Olson ER, Greenberg EP, (2006). Novel Pseudomonas aeruginosa quorum-sensing inhibitors identified in an ultra-high-throughput screen. Antimicrob Agents Chemother 50: 3674-3679. (Pubitemid 44684880)
126. Mulcahy LR, Burns JL, Lory S, Lewis K, (2010). Emergence of Pseudomonas aeruginosa strains producing high levels of persister cells in patients with cystic fibrosis. J Bacteriol 192: 6191-6199.
127. Nakai T, Park SC, (2002). Bacteriophage therapy of infectious diseases in aquaculture. Res Microbiol 153: 13-18. (Pubitemid 34112573)
128. Nalca Y, Jansch L, Bredenbruch F, Geffers R, Buer J, Haussler S, (2006). Quorum-sensing antagonistic activities of azithromycin in Pseudomonas aeruginosa PAO1: a global approach. Antimicrob Agents Chemother 50: 1680-1688.
129. Nordmann P, Cuzon G, Naas T, (2009). The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect Dis 9: 228-236.
130. Pan B, Huang R, Zheng L, Chen C, Han S, Qu D, et al,. (2011). Thiazolidione derivatives as novel antibiofilm agents: design, synthesis, biological evaluation, and structure-activity relationships. Eur J Med Chem 46: 819-824.
131. Parsek MR, Val DL, Hanzelka BL, Cronan JE Jr, Greenberg EP, (1999). Acyl homoserine-lactone quorum-sensing signal generation. Proc Natl Acad Sci U S A 96: 4360-4365. (Pubitemid 29190341)
132. Patrick DM, Hutchinson J, (2009). Antibiotic use and population ecology: how you can reduce your 'resistance footprint'. CMAJ 180: 416-421.
133. Pechere JC, (2001). Azithromycin reduces the production of virulence factors in Pseudomonas aeruginosa by inhibiting quorum sensing. Jpn J Antibiot 54 (Suppl. C): 87-89. (Pubitemid 33759445)
134. Persson T, Givskov M, Nielsen J, (2005). Quorum sensing inhibition: targeting chemical communication in Gram-negative bacteria. Curr Med Chem 12: 3103-3115. (Pubitemid 41749253)
135. Potera C, (1999). Forging a link between biofilms and disease. Science 283: 1837-1839. (Pubitemid 29144179)
136. Projan SJ, (2003). Why is big pharma getting out of antibacterial drug discovery? Curr Opin Microbiol 6: 427-430. (Pubitemid 37345405)
137. Purevdorj-Gage B, Costerton WJ, Stoodley P, (2005). Phenotypic differentiation and seeding dispersal in non-mucoid and mucoid Pseudomonas aeruginosa biofilms. Microbiology 151: 1569-1576. (Pubitemid 40711803)
138. Rasmussen TB, Skindersoe ME, Bjarnsholt T, Phipps RK, Christensen KB, Jensen PO, et al,. (2005). Identity and effects of quorum-sensing inhibitors produced by Penicillium species. Microbiology 151: 1325-1340. (Pubitemid 40711780)
139. Rice SA, Tan CH, Mikkelsen PJ, Kung V, Woo J, Tay M, et al,. (2009). The biofilm life cycle and virulence of Pseudomonas aeruginosa are dependent on a filamentous prophage. ISME J 3: 271-282.
140. Roberts ME, Stewart PS, (2005). Modelling protection from antimicrobial agents in biofilms through the formation of persister cells. Microbiology 151: 75-80. (Pubitemid 40207671)
141. Rogers GB, Hoffman LR, Whiteley M, Daniels TW, Carroll MP, Bruce KD, (2010a). Revealing the dynamics of polymicrobial infections: implications for antibiotic therapy. Trends Microbiol 18: 357-364.
142. Rogers GB, Marsh P, Stressmann AF, Allen CE, Daniels TV, Carroll MP, et al,. (2010b). The exclusion of dead bacterial cells is essential for accurate molecular analysis of clinical samples. Clin Microbiol Infect 16: 1656-1658.
143. Rogers GB, Hoffman LR, Döring G, (2011). Novel concepts in evaluating antimicrobial therapy for bacterial lung infections in patients with cystic fibrosis. J Cystic Fibrosis DOI: 10.1016/j.jcf.2011.06.014.
144. Rolinson GN, Geddes AM, (2007). The 50th anniversary of the discovery of 6-aminopenicillanic acid (6-APA). Int J Antimicrob Agents 29: 3-8. (Pubitemid 44959773)
145. Rotem E, Loinger A, Ronin I, Levin-Reisman I, Gabay C, Shoresh N, et al,. (2010). Regulation of phenotypic variability by a threshold-based mechanism underlies bacterial persistence. Proc Natl Acad Sci U S A 107: 12541-12546.
146. Sabuncu E, David J, Bernede-Bauduin C, Pepin S, Leroy M, Boelle PY, et al,. (2009). Significant reduction of antibiotic use in the community after a nationwide campaign in France, 2002-2007. PLoS Med 6: e1000084.
147. Saiman L, Marshall BC, Mayer-Hamblett N, Burns JL, Quittner AL, Cibene DA, et al,. (2003). Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 290: 1749-1756. (Pubitemid 37430625)
148. Sauer K, Cullen MC, Rickard AH, Zeef LA, Davies DG, Gilbert P, (2004). Characterization of nutrient-induced dispersion in Pseudomonas aeruginosa PAO1 biofilm. J Bacteriol 186: 7312-7326. (Pubitemid 39383116)
149. Schaefer AL, Hanzelka BL, Eberhard A, Greenberg EP, (1996). Quorum sensing in Vibrio fischeri: probing autoinducer-LuxR interactions with autoinducer analogs. J Bacteriol 178: 2897-2901. (Pubitemid 26144048)
150. Schleheck D, Barraud N, Klebensberger J, Webb JS, McDougald D, Rice SA, et al,. (2009). Pseudomonas aeruginosa PAO1 preferentially grows as aggregates in liquid batch cultures and disperses upon starvation. PLoS ONE 4: e5513.
151. Scholl D, Adhya S, Merril C, (2005). Escherichia coli K1's capsule is a barrier to bacteriophage T7. Appl Environ Microbiol 71: 4872-4874. (Pubitemid 41129547)
152. Schumacher MA, Piro KM, Xu W, Hansen S, Lewis K, Brennan RG, (2009). Molecular mechanisms of HipA-mediated multidrug tolerance and its neutralization by HipB. Science 323: 396-401.
153. Shah D, Zhang Z, Khodursky A, Kaldalu N, Kurg K, Lewis K, (2006). Persisters: a distinct physiological state of E. coli. BMC Microbiol 6: 53.
154. Shea KM, American Academy of Pediatrics Committee on Environmental Health, American Academy of Pediatrics Committee on Infectious Diseases (2004). Nontherapeutic use of antimicrobial agents in animal agriculture: implications for pediatrics. Pediatrics 114: 862-868. (Pubitemid 41529552)
155. Sheng H, Knecht HJ, Kudva IT, Hovde CJ, (2006). Application of bacteriophages to control intestinal Escherichia coli O157:H7 levels in ruminants. Appl Environ Microbiol 72: 5359-5366.
156. Shiner EK, Terentyev D, Bryan A, Sennoune S, Martinez-Zaguilan R, Li G, et al,. (2006). Pseudomonas aeruginosa autoinducer modulates host cell responses through calcium signalling. Cell Microbiol 8: 1601-1610. (Pubitemid 44350019)
157. Shlaes DM, Moellering RC Jr, (2002). The United States Food and Drug Administration and the end of antibiotics. Clin Infect Dis 34: 420-422. (Pubitemid 34062252)
158. Simm R, Morr M, Kader A, Nimtz M, Romling U, (2004). GGDEF and EAL domains inversely regulate cyclic di-GMP levels and transition from sessility to motility. Mol Microbiol 53: 1123-1134. (Pubitemid 39120434)
159. Skindersoe ME, Alhede M, Phipps R, Yang L, Jensen PO, Rasmussen TB, et al,. (2008). Effects of antibiotics on quorum sensing in Pseudomonas aeruginosa. Antimicrob Agents Chemother 52: 3648-3663.
160. Sofer D, Gilboa-Garber N, Belz A, Garber NC, (1999). 'Subinhibitory' erythromycin represses production of Pseudomonas aeruginosa lectins, autoinducer and virulence factors. Chemotherapy 45: 335-341. (Pubitemid 29410812)
161. Spellberg B, Powers JH, Brass EP, Miller LG, Edwards JE Jr, (2004). Trends in antimicrobial drug development: implications for the future. Clin Infect Dis 38: 1279-1286. (Pubitemid 38608571)
162. Sperandio V, (2007). Novel approaches to bacterial infection therapy by interfering with bacteria-to-bacteria signaling. Expert Rev Anti Infect Ther 5: 271-276. (Pubitemid 46681745)
163. Spoering AL, Lewis K, (2001). Biofilms and planktonic cells of Pseudomonas aeruginosa have similar resistance to killing by antimicrobials. J Bacteriol 183: 6746-6751. (Pubitemid 33064186)
164. Sulakvelidze A, Alavidze Z, Morris JG Jr, (2001). Bacteriophage therapy. Antimicrob Agents Chemother 45: 649-659. (Pubitemid 32182003)
165. Summers WC, (2001). Bacteriophage therapy. Annu Rev Microbiol 55: 437-451. (Pubitemid 32978113)
166. Swift S, Karlyshev AV, Fish L, Durant EL, Winson MK, Chhabra SR, et al,. (1997). Quorum sensing in Aeromonas hydrophila and Aeromonas salmonicida: identification of the LuxRI homologs AhyRI and AsaRI and their cognate N-acylhomoserine lactone signal molecules. J Bacteriol 179: 5271-5281. (Pubitemid 27387591)
167. Swift S, Lynch MJ, Fish L, Kirke DF, Tomas JM, Stewart GS, et al,. (1999). Quorum sensing-dependent regulation and blockade of exoprotease production in Aeromonas hydrophila. Infect Immun 67: 5192-5199. (Pubitemid 29455291)
168. Talbot GH, Bradley J, Edwards JE Jr, Gilbert D, Scheld M, Bartlett JG, et al,. (2006). Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin Infect Dis 42: 657-668. (Pubitemid 43271379)
169. Tateda K, Comte R, Pechere JC, Kohler T, Yamaguchi K, Van Delden C, (2001). Azithromycin inhibits quorum sensing in Pseudomonas aeruginosa. Antimicrob Agents Chemother 45: 1930-1933. (Pubitemid 32466379)
170. Thormann KM, Duttler S, Saville RM, Hyodo M, Shukla S, Hayakawa Y, et al,. (2006). Control of formation and cellular detachment from Shewanella oneidensis MR-1 biofilms by cyclic di-GMP. J Bacteriol 188: 2681-2691.
171. Ueda A, Attila C, Whiteley M, Wood TK, (2009). Uracil influences quorum sensing and biofilm formation in Pseudomonas aeruginosa and fluorouracil is an antagonist. Microb Biotechnol 2: 62-74.
172. Uroz S, Dessaux Y, Oger P, (2009). Quorum sensing and quorum quenching: the yin and yang of bacterial communication. Chembiochem 10: 205-216.
173. Vatopoulos A, (2008). High rates of metallo-β-lactamase-producing Klebsiella pneumoniae in Greece-a review of the current evidence. Euro Surveill 13: 8023.
174. Vazquez-Laslop N, Lee H, Neyfakh AA, (2006). Increased persistence in Escherichia coli caused by controlled expression of toxins or other unrelated proteins. J Bacteriol 188: 3494-3497. (Pubitemid 43726213)
175. Viducic D, Ono T, Murakami K, Susilowati H, Kayama S, Hirota K, et al,. (2006). Functional analysis of spoT, relA and dksA genes on quinolone tolerance in Pseudomonas aeruginosa under nongrowing condition. Microbiol Immunol 50: 349-357. (Pubitemid 46277501)
176. Wagner VE, Bushnell D, Passador L, Brooks AI, Iglewski BH, (2003). Microarray analysis of Pseudomonas aeruginosa quorum-sensing regulons: effects of growth phase and environment. J Bacteriol 185: 2080-2095. (Pubitemid 36363168)
177. Wang BY, Kuramitsu HK, (2005). Interactions between oral bacteria: inhibition of Streptococcus mutans bacteriocin production by Streptococcus gordonii. Appl Environ Microbiol 71: 354-362. (Pubitemid 40116289)
178. Waters CM, Bassler BL, (2005). Quorum sensing: cell-to-cell communication in bacteria. Annu Rev Cell Dev Biol 21: 319-346. (Pubitemid 41740638)
179. Webb JS, Thompson LS, James S, Charlton T, Tolker-Nielsen T, Koch B, et al,. (2003). Cell death in Pseudomonas aeruginosa biofilm development. J Bacteriol 185: 4585-4592. (Pubitemid 36890507)
180. Wenzel RP, (2004). The antibiotic pipeline-challenges, costs, and values. N Engl J Med 351: 523-526.
181. Westwater C, Kasman LM, Schofield DA, Werner PA, Dolan JW, Schmidt MG, et al,. (2003). Use of genetically engineered phage to deliver antimicrobial agents to bacteria: an alternative therapy for treatment of bacterial infections. Antimicrob Agents Chemother 47: 1301-1307. (Pubitemid 36368589)
182. Williams SC, Patterson EK, Carty NL, Griswold JA, Hamood AN, Rumbaugh KP, (2004). Pseudomonas aeruginosa autoinducer enters and functions in mammalian cells. J Bacteriol 186: 2281-2287. (Pubitemid 38451830)
183. Withey S, Cartmell E, Avery LM, Stephenson T, (2005). Bacteriophages-potential for application in wastewater treatment processes. Sci Total Environ 339: 1-18. (Pubitemid 40312237)
184. Wu H, Song Z, Hentzer M, Andersen JB, Molin S, Givskov M, et al,. (2004). Synthetic furanones inhibit quorum-sensing and enhance bacterial clearance in Pseudomonas aeruginosa lung infection in mice. J Antimicrob Chemother 53: 1054-1061. (Pubitemid 38807648)
185. Yates EA, Philipp B, Buckley C, Atkinson S, Chhabra SR, Sockett RE, et al,. (2002). N-acylhomoserine lactones undergo lactonolysis in a pH-, temperature-, and acyl chain length-dependent manner during growth of Yersinia pseudotuberculosis and Pseudomonas aeruginosa. Infect Immun 70: 5635-5646.
186. Yong D, Toleman MA, Giske CG, Cho HS, Sundman K, Lee K, et al,. (2009). Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. Antimicrob Agents Chemother 53: 5046-5054.
187. Zhan SK, Tang SL, Guo YD, Bloom G, (1998). Drug prescribing in rural health facilities in China: implications for service quality and cost. Trop Doct 28: 42-48. (Pubitemid 28091994)
188. Zhang LH, Dong YH, (2004). Quorum sensing and signal interference: diverse implications. Mol Microbiol 53: 1563-1571.
189. Zhu J, Beaber JW, More MI, Fuqua C, Eberhard A, Winans SC, (1998). Analogs of the autoinducer 3-oxooctanoyl-homoserine lactone strongly inhibit activity of the TraR protein of Agrobacterium tumefaciens. J Bacteriol 180: 5398-5405. (Pubitemid 28471536)